drugset / Trial / NCT01229566
Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective is to determine the efficacy of AKR963 compared to placebo and active comparator in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 1500 mg/dL.
Timeline
- Start
- 2010-10
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AKR-963 | Unknown | 3600 mg | — |
Indications
No indication recorded.